The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PSMA heterogeneity and DNA repair defects in prostate cancer.
 
Alec Paschalis
No Relationships to Disclose
 
Beshara Sheehan
No Relationships to Disclose
 
Ruth Riisnaes
No Relationships to Disclose
 
Daniel Nava Rodrigues
No Relationships to Disclose
 
Bora Gurel
No Relationships to Disclose
 
Claudia Bertan
No Relationships to Disclose
 
Ana Ferreira
No Relationships to Disclose
 
Maryou B. Lambros
No Relationships to Disclose
 
George Seed
No Relationships to Disclose
 
Wei Yuan
Other Relationship - Yinghuahengrui
 
David Dolling
Travel, Accommodations, Expenses - Pfizer
 
Jon Welti
No Relationships to Disclose
 
Antje Neeb
Research Funding - Bayer; Merck Serono; Sierra Oncology
 
Semini Sumanasuriya
No Relationships to Disclose
 
Pasquale Rescigno
No Relationships to Disclose
 
Diletta Bianchini
Honoraria - Janssen
Travel, Accommodations, Expenses - Janssen
 
Nina Tunariu
No Relationships to Disclose
 
Suzanne Carreira
No Relationships to Disclose
 
Adam Sharp
Speakers' Bureau - Astellas Pharma
Travel, Accommodations, Expenses - Genentech/Roche; Sanofi
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex